BR112023002150A2 - Anticorpos direcionando egfr e uso dos mesmos - Google Patents

Anticorpos direcionando egfr e uso dos mesmos

Info

Publication number
BR112023002150A2
BR112023002150A2 BR112023002150A BR112023002150A BR112023002150A2 BR 112023002150 A2 BR112023002150 A2 BR 112023002150A2 BR 112023002150 A BR112023002150 A BR 112023002150A BR 112023002150 A BR112023002150 A BR 112023002150A BR 112023002150 A2 BR112023002150 A2 BR 112023002150A2
Authority
BR
Brazil
Prior art keywords
proteins
antibodies targeting
targeting egfr
egfr
pharmaceutical compositions
Prior art date
Application number
BR112023002150A
Other languages
English (en)
Inventor
Grinberg Asya
Sean Juo Zong
Liharska Katia
Ryan Morgan Christopher
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of BR112023002150A2 publication Critical patent/BR112023002150A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

ANTICORPOS DIRECIONANDO EGFR E USO DOS MESMOS. São reveladas proteínas com domínios variáveis de cadeia pesada e de cadeia leve de anticorpo que podem ser pareados para formar um sítio de ligação ao antígeno direcionando EGFR em uma célula, composições farmacêuticas compreendendo tais proteínas, e métodos terapêuticos usando tais proteínas e composições farmacêuticas, incluindo para o tratamento de câncer.
BR112023002150A 2020-08-05 2021-08-05 Anticorpos direcionando egfr e uso dos mesmos BR112023002150A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063061507P 2020-08-05 2020-08-05
PCT/US2021/044688 WO2022031935A1 (en) 2020-08-05 2021-08-05 Antibodies targeting egfr and use thereof

Publications (1)

Publication Number Publication Date
BR112023002150A2 true BR112023002150A2 (pt) 2023-05-02

Family

ID=77520815

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002150A BR112023002150A2 (pt) 2020-08-05 2021-08-05 Anticorpos direcionando egfr e uso dos mesmos

Country Status (11)

Country Link
US (1) US20230279121A1 (pt)
EP (1) EP4192874A1 (pt)
JP (1) JP2023536627A (pt)
KR (1) KR20230042753A (pt)
CN (1) CN116547302A (pt)
AU (1) AU2021320253A1 (pt)
BR (1) BR112023002150A2 (pt)
CA (1) CA3188204A1 (pt)
IL (1) IL300246A (pt)
MX (1) MX2023001556A (pt)
WO (1) WO2022031935A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
ATE373078T1 (de) 2000-02-24 2007-09-15 Xcyte Therapies Inc Gleichzeitige stimulation und konzentration von zellen
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
RS63964B1 (sr) 2005-08-23 2023-03-31 Univ Pennsylvania Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
EP3072961A1 (en) 2010-04-16 2016-09-28 Children's Medical Center Corporation Sustained polypeptide expression from synthetic, modified rnas and uses thereof
SG194111A1 (en) * 2011-04-07 2013-11-29 Amgen Inc Novel egfr binding proteins
CN103648525B (zh) 2011-05-06 2016-08-24 由卫生与公共服务部部长代表的美国政府 靶向间皮素的重组免疫毒素
NZ630563A (en) 2012-09-27 2017-04-28 Merus Nv Bispecific igg antibodies as t cell engagers
WO2014164693A2 (en) 2013-03-12 2014-10-09 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
IL295906A (en) 2014-03-21 2022-10-01 Abbvie Inc Antibodies against egfr and drug antibody conjugates
WO2015164739A1 (en) 2014-04-25 2015-10-29 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
MX2018005229A (es) 2015-12-09 2019-04-29 F Hoffmann­La Roche Ag Anticuerpo anti-cd20 de tipo ii y usos del mismo.
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
KR20200118080A (ko) 2018-02-08 2020-10-14 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d 수용체를 표적화하는 항체 가변 도메인

Also Published As

Publication number Publication date
WO2022031935A1 (en) 2022-02-10
CA3188204A1 (en) 2022-02-10
AU2021320253A1 (en) 2023-03-02
IL300246A (en) 2023-03-01
EP4192874A1 (en) 2023-06-14
JP2023536627A (ja) 2023-08-28
US20230279121A1 (en) 2023-09-07
CN116547302A (zh) 2023-08-04
KR20230042753A (ko) 2023-03-29
MX2023001556A (es) 2023-03-08

Similar Documents

Publication Publication Date Title
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
MX2020008336A (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
BR112022006817A2 (pt) Anticorpos direcionados a flt3 e uso dos mesmos
BR112018011336A2 (pt) anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer
BR112016030447A2 (pt) diacorpo biespecífico de fc capaz de ligação imunoespecífica a um epítopo de pd-1 e a um epítopo de lag-3, composição farmacêutica, método para tratamento de câncer, e, método para tratamento de uma doença associada com a presença de um patógeno
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
PE20091234A1 (es) Construcciones de union de antigenos
BR112016030686A2 (pt) anticorpos anti tau humanizados
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
BR112022022418A2 (pt) Anticorpos de alvejamento de clec12a e uso dos mesmos
BR112016024214B8 (pt) Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
PE20221326A1 (es) Anticuerpos anti-mertk y metodos de uso de los mismos
BR112021020867A2 (pt) Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
AR114544A1 (es) Proteínas de unión multiespecíficas que unen a bcma, nkg2d y cd16, y métodos de uso
BR112022017508A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
BR112023002150A2 (pt) Anticorpos direcionando egfr e uso dos mesmos
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
BR112022001336A2 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
BR112022009482A2 (pt) Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo
BR112022001329A2 (pt) Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo